A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

Status Recruiting

Clinical Trial Summary

A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients with Prader-Willi Syndrome

Clinical Trial Description

This is a Phase 2, open-label study to investigate the effects of ARD-101 in subjects with Prader-Willi Syndrome. The study will consist of a Screening Period (up to 28 days), a Treatment Period (28 days), and a Follow-up Period (End-of-Study Visit within 14 days after receiving the last dose of ARD-101). The screening procedures will be initiated upon completion of the informed consent process. Following completion of screening procedures and confirmation of eligibility, subjects will be enrolled to receive ARD-101 in an outpatient setting and will be instructed to visit the clinical center periodically for safety and efficacy assessments. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05153434
Study type	Interventional
Source	Aardvark Therapeutics, Inc.
Contact	Andreas Niethammer, MD, PhD
Phone	858-349-4820
Email	AndreasNiethammer@aardvarktherapeutics.com
Status	Recruiting
Phase	Phase 2
Start date	May 27, 2022
Completion date	March 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05032326` - Long-term Interventional Follow-up Study of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial	Phase 3
Completed	`NCT04526379` - Study of Emotion and Cognition Abilities of Children With PWS and Proposition of an Innovative Remediation	N/A
Terminated	`NCT03458416` - A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome	Phase 2
Completed	`NCT03718416` - Natural History Study of Serious Medical Events in PWS
Completed	`NCT05322096` - Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome	Phase 2
Completed	`NCT02205450` - Growth Hormone in Children Under 2 Years With Prader-Willi in Hospital of Sabadell
Terminated	`NCT02179151` - Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome	Phase 3
Completed	`NCT00375089` - Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity	N/A
Completed	`NCT00004351` - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes	N/A
Recruiting	`NCT05938543` - Cerebellar TMS and Satiety in Prader-Willi Syndrome	N/A
Suspended	`NCT05879614` - An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)	Phase 2
Recruiting	`NCT03031626` - Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome	Phase 4
Withdrawn	`NCT04086810` - An Open-Label Study of DCCR Tablet in Patients With PWS	Phase 3
Completed	`NCT02629991` - Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome	Phase 2
Recruiting	`NCT02297022` - Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome	Phase 1
Not yet recruiting	`NCT02263781` - PREPL in Health and Disease	N/A
Completed	`NCT00551343` - Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome	N/A
Recruiting	`NCT06448871` - Ultrasound to Assess Sarcopenia in Prader Willi Syndrome
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Recruiting	`NCT05939453` - Impact of Bright Light Therapy on Prader-Willi Syndrome	N/A